Skip to content
What_are_troches5 min readStandard

How Are Ketamine Troches Compounded?

Learn how compounding pharmacies make ketamine troches, the ingredients used, quality standards followed, and what makes one pharmacy better than another.

The Compounding Process for Ketamine Troches

Ketamine troches are not manufactured in a commercial pharmaceutical factory. They are custom-made by licensed compounding pharmacies, one batch at a time, based on an individual prescription from a licensed prescriber. Understanding how this process works helps patients ask the right questions and choose pharmacies that meet the highest quality standards.

What Is Pharmaceutical Compounding?

Pharmaceutical compounding is the practice of creating a customized medication for an individual patient when a commercially available product does not meet that patient's needs. The FDA permits this practice under specific regulatory frameworks, primarily Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs compounding done by licensed pharmacists for individual prescriptions.

For ketamine, there is no commercially approved sublingual troche formulation. The only FDA-approved ketamine-derived product for psychiatric use is esketamine nasal spray (Spravato), which is an entirely different molecule and delivery system. Compounded ketamine troches fill the gap, allowing physicians to prescribe a sublingual format that can be used at home.

Ingredients in a Compounded Ketamine Troche

Every ketamine troche contains both active and inactive ingredients:

Active Ingredient

Ketamine hydrochloride (ketamine HCl) is the pharmacologically active component. The prescriber specifies the exact milligram dose per troche — commonly ranging from 50 mg to 400 mg depending on the indication and patient response. Compounding pharmacies source ketamine HCl as an API (active pharmaceutical ingredient) from FDA-registered suppliers.

Inactive Ingredients (Excipients)

The troche base determines how the lozenge holds together, dissolves, and releases the drug. Common excipient choices include:

  • Polyethylene glycol (PEG) bases: The most commonly used troche bases, PEG 1000 and PEG 3350 are mixed in ratios that control the melt point and dissolution rate. A harder base dissolves more slowly; a softer one dissolves faster.
  • Gelatin or acacia: Sometimes used as binding agents to give the troche its cohesive structure.
  • Flavoring agents: Mint, cherry, watermelon, grape, and bubble gum are popular choices to mask ketamine's characteristic bitter taste. These are pharmaceutical-grade flavor concentrates, not culinary flavorings.
  • Sweeteners: Sucralose or stevia may be included to improve palatability.
  • Preservatives: Some formulations include benzalkonium chloride or methylparaben, though many pharmacies offer preservative-free versions.
  • Colorants: Cosmetic-grade dyes are sometimes used to differentiate doses or improve patient adherence.

The Manufacturing Steps

A compounding pharmacist follows a specific, documented procedure for each batch:

Step 1: Prescription Verification

Before compounding begins, a licensed pharmacist verifies the prescription for completeness, appropriate dosing, absence of dangerous drug interactions, and practitioner authority to prescribe controlled substances. Ketamine is a Schedule III controlled substance, so both the prescriber and pharmacy must maintain DEA registrations.

Step 2: Ingredient Weighing and Quality Control

The ketamine HCl API is weighed on a calibrated analytical balance, typically accurate to 0.1 mg. All excipients are weighed according to the formulation's master formula record — a standardized document that specifies exact amounts of every ingredient, equipment settings, and procedural steps.

Step 3: Base Preparation

The PEG or other base materials are melted at a controlled temperature, typically between 50°C and 65°C, using a water bath or hot plate with temperature monitoring. Overheating can degrade the base; underheating produces an inconsistent texture.

Step 4: Incorporation of Ketamine and Excipients

The weighed ketamine HCl is incorporated into the melted base using geometric dilution — a technique where the API is first mixed with a small amount of base, then that mixture is progressively combined with larger amounts. This ensures uniform distribution of the drug throughout the batch. Flavoring and sweeteners are added and mixed thoroughly. The choice of these active and inactive ingredients directly affects the troche's taste, dissolution rate, and stability.

Step 5: Pouring and Cooling

The molten mixture is poured into calibrated molds, each cavity holding a defined volume that corresponds to the target troche weight. Molds are cooled at controlled temperature — either at room temperature or in a refrigerator — to produce uniform, smooth troches.

Step 6: Visual Inspection and Quality Testing

Each troche is inspected for visual defects: air bubbles, irregular shape, surface cracks, or color inconsistencies. Many accredited pharmacies perform potency testing using high-performance liquid chromatography (HPLC) on a sample from each batch. This confirms that the actual ketamine content matches the labeled amount within acceptable limits (typically ±10%).

Step 7: Packaging and Labeling

Troches are packaged in individual blister packs or sealed containers, labeled with patient name, prescriber, drug name and dose, lot number, expiration date, storage instructions, and required DEA and pharmacy information.

Quality Standards Governing Compounding Pharmacies

USP Chapter 795

The United States Pharmacopeia (USP) Chapter 795 establishes standards for non-sterile compounding, which covers troches. Requirements include documentation of formulas, equipment calibration records, beyond-use dating, personnel training, and environmental controls.

PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB) is a voluntary accreditation program that evaluates compounding pharmacies against rigorous quality standards. PCAB-accredited pharmacies undergo on-site inspections and meet requirements that often exceed state board minimums. When choosing a compounding pharmacy for ketamine troches, PCAB accreditation is one of the strongest quality signals available.

State Board Oversight

Each state's board of pharmacy regulates compounding pharmacies within its jurisdiction. Requirements vary by state, which is one reason patients and prescribers should work with pharmacies that voluntarily pursue higher-level accreditation.

What Patients Should Ask Their Pharmacy

Before accepting troches from any compounding pharmacy, consider asking:

  1. Do you hold PCAB accreditation?
  2. Do you perform potency testing on ketamine troche batches?
  3. What troche base do you use, and why?
  4. Where do you source your ketamine HCl API?
  5. What is the beyond-use date for your troches, and how was it determined?
  6. Do you offer preservative-free formulations?

A pharmacy that answers these questions transparently and confidently is a pharmacy worth trusting.

Key Takeaways

  • Ketamine troches are custom-compounded by licensed pharmacies, not mass-manufactured.
  • Active ingredient is ketamine HCl; inactive ingredients include PEG base, flavoring, sweeteners, and sometimes preservatives.
  • The compounding process involves precise weighing, controlled melting, geometric dilution, and quality inspection.
  • USP 795 and PCAB accreditation are the primary quality benchmarks to look for.
  • Patients should ask about potency testing and API sourcing before using any compounding pharmacy.

References

  • StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
  • PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
  • MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
  • NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
  • WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches

Share

Share on X
Share on LinkedIn
Share on Facebook
Send via Email
Copy URL